Innate Pharma is strengthening its resources in Toll-like receptor (TLR) pharmacology by entering into two strategic alliances - the acquisition of undisclosed assets from Schering-Plough and a R&D collaboration with the Institut de cancérologie Gustave-Roussy (IGR) which includes the transfer of technologies from IGR to Innate Pharma.